Dejan Maglic
Overview
Explore the profile of Dejan Maglic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schonherr H, Ayaz P, Taylor A, Casaletto J, Toure B, Moustakas D, et al.
Proc Natl Acad Sci U S A
. 2024 Feb;
121(6):e2317756121.
PMID: 38300868
Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors harboring alterations, but the toxicity of...
2.
Subbiah V, Sahai V, Maglic D, Bruderek K, Toure B, Zhao S, et al.
Cancer Discov
. 2023 Jun;
13(9):2012-2031.
PMID: 37270847
Significance: Patients with FGFR2-driven cancers derive limited benefit from pan-FGFRi due to multiple FGFR1-4-mediated toxicities and acquired FGFR2 resistance mutations. RLY-4008 is a highly selective FGFR2 inhibitor that targets primary...
3.
Cheung P, Xiol J, Dill M, Yuan W, Panero R, Roper J, et al.
Cell Stem Cell
. 2020 Jul;
27(4):590-604.e9.
PMID: 32730753
Although the Hippo transcriptional coactivator YAP is considered oncogenic in many tissues, its roles in intestinal homeostasis and colorectal cancer (CRC) remain controversial. Here, we demonstrate that the Hippo kinases...
4.
Wang Y, Xu X, Maglic D, Dill M, Mojumdar K, Ng P, et al.
Cell Rep
. 2018 Nov;
25(5):1304-1317.e5.
PMID: 30380420
Hippo signaling has been recognized as a key tumor suppressor pathway. Here, we perform a comprehensive molecular characterization of 19 Hippo core genes in 9,125 tumor samples across 33 cancer...
5.
Maglic D, Schlegelmilch K, Dost A, Panero R, Dill M, Calogero R, et al.
EMBO J
. 2018 Jul;
37(17).
PMID: 30037824
The mammalian Hippo signaling pathway, through its effectors YAP and TAZ, coerces epithelial progenitor cell expansion for appropriate tissue development or regeneration upon damage. Its ability to drive rapid tissue...
6.
Maglic D, Stovall D, Cline J, Fry E, Mallakin A, Taneja P, et al.
J Pathol
. 2014 Dec;
236(1):90-102.
PMID: 25537728
Our recent work has indicated that the DMP1 locus on 7q21, encoding a haplo-insufficient tumour suppressor, is hemizygously deleted at a high frequency in breast cancer. The locus encodes DMP1α...
7.
Fry E, Taneja P, Maglic D, Zhu S, Sui G, Inoue K
PLoS One
. 2013 Nov;
8(10):e77870.
PMID: 24205004
Our recent study shows a pivotal role of Dmp1 in quenching hyperproliferative signals from HER2 to the Arf-p53 pathway as a safety mechanism to prevent breast carcinogenesis. To directly demonstrate...
8.
Stovall D, Wan M, Miller L, Cao P, Maglic D, Zhang Q, et al.
Am J Pathol
. 2013 Sep;
183(5):1645-1653.
PMID: 24012678
Both epigenetic silencing and genetic deletion of tumor suppressors contribute to the development and progression of breast cancer. SOX7 is a transcription factor important to development, and its down-regulation has...
9.
Frazier D, Kendig R, Kai F, Maglic D, Sugiyama T, Morgan R, et al.
Cancer Res
. 2012 Feb;
72(7):1740-50.
PMID: 22331460
The transcription factor Dmp1 is a Ras/HER2-activated haplo-insufficient tumor suppressor that activates the Arf/p53 pathway of cell-cycle arrest. Recent evidence suggests that Dmp1 may activate p53 independently of Arf in...
10.
Taneja P, Zhu S, Maglic D, Fry E, Kendig R, Inoue K
Clin Med Insights Oncol
. 2011 Aug;
5:235-57.
PMID: 21836819
Cancer is caused by multiple genetic alterations leading to uncontrolled cell proliferation through multiple pathways. Malignant cells arise from a variety of genetic factors, such as mutations in tumor suppressor...